BCTXZHIGH SIGNALFINANCIAL10-K

BCTXZ underwent a dramatic share count reduction from 36.2 million to 1.9 million shares outstanding, likely indicating a significant reverse stock split.

The massive 95% reduction in outstanding shares from 36.2 million to 1.9 million shares typically signals a reverse stock split, often implemented by struggling companies to meet exchange listing requirements or improve share price perception. This action frequently indicates underlying financial distress and can dilute existing shareholders' economic interests despite maintaining their proportional ownership.

Comparing 2025-10-16 vs 2024-10-29View on EDGAR →
FINANCIAL ANALYSIS

The company's financial position showed mixed signals with R&D expenses declining 21.7% to $21.3M and operating losses narrowing from -$33.3M to -$27.2M, suggesting some cost discipline. However, operating cash flow deteriorated further to -$28.2M, while current liabilities decreased substantially to $4.0M. The dramatic share count reduction overshadows these operational metrics and represents the most significant development for investors.

FINANCIAL STATEMENT CHANGES
Interest Expense
P&L
-98.8%
$79K979

Interest expense declined — debt repayment or refinancing at lower rates improving earnings quality.

Current Liabilities
Balance Sheet
-46.7%
$7.5M$4.0M

Current liabilities reduced — improved short-term financial position and working capital health.

R&D Expense
P&L
-21.7%
$27.2M$21.3M

R&D spending cut 21.7% — could signal cost discipline or concerning reduction in innovation investment.

Accounts Receivable
Balance Sheet
-21.7%
$24K$19K

Receivables declined — improved collection efficiency or conservative revenue recognition.

Operating Income
P&L
+18.4%
-$33.3M-$27.2M

Operating income improving — cost discipline or growing revenue base absorbing fixed costs.

Operating Cash Flow
Cash Flow
-16.8%
-$24.1M-$28.2M

Operating cash flow softened — monitor whether temporary working capital timing or structural deterioration.

LANGUAGE CHANGES
NEW — 2025-10-16
PRIOR — 2024-10-29
ADDED
As of October 15, 2025, 1,883,906 shares of the registrant s common shares, no par value per share, were issued and outstanding.
Changes in legislation and regulations may affect our revenue and profitability There is substantial doubt about our ability to continue as a going concern We are highly dependent on our key personnel; We have an unproven market for our product candidates; We are a pre-revenue clinical stage company; Short sellers may be manipulative and may drive down the market price of our common shares; Future issuance of our common shares could dilute the interests of existing shareholders 3 PART I ITEM BUSINESS BUSINESS Overview of the Company BriaCell Therapeutics Corp.
The Company is currently advancing its Bria-IMT targeted immunotherapy in combination with an immune check point inhibitor (Retifanlimab) in a pivotal 1 Phase 3 study in metastatic breast cancer (listed on ClinicalTrials.gov as NCT06072612 ).
6.7-9.8 months 2 for similar patients reported in the literature in its Phase 2 study of Bria-IMT combination study with retifanlimab.
A completed Bria-IMT Phase 1/2 combination study with retifanlimab (an anti-PD1 antibody manufactured by Incyte) confirmed tolerability and early-stage efficacy (listed on ClinicalTrials.gov as NCT03328026 ).
+7 more — sign up free →
REMOVED
As of October 28, 2024, 36,183,161 shares of the registrant s common shares, no par value per share, were issued and outstanding.
( BriaPro ) may not generate revenue as expected; Clinical trials involve a lengthy and expensive process with uncertain outcomes, and results of earlier studies and trials may not be predictive of future trial results; Future issuance of our common shares could dilute the interests of existing shareholders; and We have a significant number of options and warrants outstanding, and while these options and warrants are outstanding, it may be more difficult to raise additional equity capital.
BUSINESS BUSINESS Overview of the Company BriaCell Therapeutics Corp.
The Company is currently advancing its Bria-IMT targeted immunotherapy in combination with an immune check point inhibitor (Retifanlimab) in a pivotal 1 Phase 3 study in metastatic breast cancer.
6.7-9.8 months 2 for similar patients reported in the literature in its Phase 2 study of Bria-IMT combination study with retifanlimab at the 2023 San Antonio Breast Cancer Symposium.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →